179 related articles for article (PubMed ID: 28415590)
1. Multiple anti-tumor effects of Reparixin on thyroid cancer.
Liotti F; De Pizzol M; Allegretti M; Prevete N; Melillo RM
Oncotarget; 2017 May; 8(22):35946-35961. PubMed ID: 28415590
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-8, but not the Related Chemokine CXCL1, Sustains an Autocrine Circuit Necessary for the Properties and Functions of Thyroid Cancer Stem Cells.
Liotti F; Collina F; Pone E; La Sala L; Franco R; Prevete N; Melillo RM
Stem Cells; 2017 Jan; 35(1):135-146. PubMed ID: 27577959
[TBL] [Abstract][Full Text] [Related]
3. Targeting CXCR1 on breast cancer stem cells: signaling pathways and clinical application modelling.
Brandolini L; Cristiano L; Fidoamore A; De Pizzol M; Di Giacomo E; Florio TM; Confalone G; Galante A; Cinque B; Benedetti E; Ruffini PA; Cifone MG; Giordano A; Alecci M; Allegretti M; Cimini A
Oncotarget; 2015 Dec; 6(41):43375-94. PubMed ID: 26517518
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of interleukin 8/C‑X-C chemokine receptor 1,/2 signaling reduces malignant features in human pancreatic cancer cells.
Fu S; Chen X; Lin HJ; Lin J
Int J Oncol; 2018 Jul; 53(1):349-357. PubMed ID: 29749433
[TBL] [Abstract][Full Text] [Related]
5. Repertaxin, an inhibitor of the chemokine receptors CXCR1 and CXCR2, inhibits malignant behavior of human gastric cancer MKN45 cells in vitro and in vivo and enhances efficacy of 5-fluorouracil.
Wang J; Hu W; Wang K; Yu J; Luo B; Luo G; Wang W; Wang H; Li J; Wen J
Int J Oncol; 2016 Apr; 48(4):1341-52. PubMed ID: 26847910
[TBL] [Abstract][Full Text] [Related]
6. A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer.
Goldstein LJ; Perez RP; Yardley D; Han LK; Reuben JM; Gao H; McCanna S; Butler B; Ruffini PA; Liu Y; Rosato RR; Chang JC
Breast Cancer Res; 2020 Jan; 22(1):4. PubMed ID: 31924241
[TBL] [Abstract][Full Text] [Related]
7. An autocrine inflammatory forward-feedback loop after chemotherapy withdrawal facilitates the repopulation of drug-resistant breast cancer cells.
Jia D; Li L; Andrew S; Allan D; Li X; Lee J; Ji G; Yao Z; Gadde S; Figeys D; Wang L
Cell Death Dis; 2017 Jul; 8(7):e2932. PubMed ID: 28703802
[TBL] [Abstract][Full Text] [Related]
8. Ladarixin, a dual CXCR1/2 inhibitor, attenuates experimental melanomas harboring different molecular defects by affecting malignant cells and tumor microenvironment.
Kemp DM; Pidich A; Larijani M; Jonas R; Lash E; Sato T; Terai M; De Pizzol M; Allegretti M; Igoucheva O; Alexeev V
Oncotarget; 2017 Feb; 8(9):14428-14442. PubMed ID: 28129639
[TBL] [Abstract][Full Text] [Related]
9. Anti-cancer Effects of HNHA and Lenvatinib by the Suppression of EMT-Mediated Drug Resistance in Cancer Stem Cells.
Lee YS; Kim SM; Kim BW; Chang HJ; Kim SY; Park CS; Park KC; Chang HS
Neoplasia; 2018 Feb; 20(2):197-206. PubMed ID: 29331886
[TBL] [Abstract][Full Text] [Related]
10. G31P, an antagonist against CXC chemokine receptors 1 and 2, inhibits growth of human prostate cancer cells in nude mice.
Liu X; Peng J; Sun W; Yang S; Deng G; Li F; Cheng JW; Gordon JR
Tohoku J Exp Med; 2012 Oct; 228(2):147-56. PubMed ID: 23019013
[TBL] [Abstract][Full Text] [Related]
11. New CXCR1/CXCR2 inhibitors represent an effective treatment for kidney or head and neck cancers sensitive or refractory to reference treatments.
Dufies M; Grytsai O; Ronco C; Camara O; Ambrosetti D; Hagege A; Parola J; Mateo L; Ayrault M; Giuliano S; Grépin R; Lagarde N; Montes M; Auberger P; Demange L; Benhida R; Pagès G
Theranostics; 2019; 9(18):5332-5346. PubMed ID: 31410218
[TBL] [Abstract][Full Text] [Related]
12. The chemokine receptors CXCR1 and CXCR2 regulate oral cancer cell behaviour.
Khurram SA; Bingle L; McCabe BM; Farthing PM; Whawell SA
J Oral Pathol Med; 2014 Oct; 43(9):667-74. PubMed ID: 24965032
[TBL] [Abstract][Full Text] [Related]
13. Synergistic suppression of a disintegrin acurhagin-C in combination with AZD4547 and reparixin on terminating development for human osteosarcoma MG-63 cell.
Shih CH; Chiang TB; Wang WJ
Biochem Biophys Res Commun; 2017 Oct; 492(3):513-519. PubMed ID: 28823917
[TBL] [Abstract][Full Text] [Related]
14. IL-8 promotes cell migration through regulating EMT by activating the Wnt/β-catenin pathway in ovarian cancer.
Wen J; Zhao Z; Huang L; Wang L; Miao Y; Wu J
J Cell Mol Med; 2020 Jan; 24(2):1588-1598. PubMed ID: 31793192
[TBL] [Abstract][Full Text] [Related]
15. CXCR1/2 pathways in paclitaxel-induced neuropathic pain.
Brandolini L; Benedetti E; Ruffini PA; Russo R; Cristiano L; Antonosante A; d'Angelo M; Castelli V; Giordano A; Allegretti M; Cimini A
Oncotarget; 2017 Apr; 8(14):23188-23201. PubMed ID: 28423567
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of CXCR1 and CXCR2 chemokine receptors attenuates acute inflammation, preserves gray matter and diminishes autonomic dysreflexia after spinal cord injury.
Marsh DR; Flemming JM
Spinal Cord; 2011 Mar; 49(3):337-44. PubMed ID: 20877331
[TBL] [Abstract][Full Text] [Related]
17. CXCL1-CXCR1/2 signaling is induced in human temporal lobe epilepsy and contributes to seizures in a murine model of acquired epilepsy.
Di Sapia R; Zimmer TS; Kebede V; Balosso S; Ravizza T; Sorrentino D; Castillo MAM; Porcu L; Cattani F; Ruocco A; Aronica E; Allegretti M; Brandolini L; Vezzani A
Neurobiol Dis; 2021 Oct; 158():105468. PubMed ID: 34358616
[TBL] [Abstract][Full Text] [Related]
18. Circular RNA circ_0067934 exhaustion expedites cell apoptosis and represses cell proliferation, migration and invasion in thyroid cancer via sponging miR-1304 and regulating CXCR1 expression.
Zhang H; Ma XP; Li X; Deng FS
Eur Rev Med Pharmacol Sci; 2019 Dec; 23(24):10851-10866. PubMed ID: 31858554
[TBL] [Abstract][Full Text] [Related]
19. Induction of CXCR2 ligands, stem cell-like phenotype, and metastasis in chemotherapy-resistant breast cancer cells.
Sharma B; Varney ML; Saxena S; Wu L; Singh RK
Cancer Lett; 2016 Mar; 372(2):192-200. PubMed ID: 26797460
[TBL] [Abstract][Full Text] [Related]
20. Functional activity of CXCL8 receptors, CXCR1 and CXCR2, on human malignant melanoma progression.
Gabellini C; Trisciuoglio D; Desideri M; Candiloro A; Ragazzoni Y; Orlandi A; Zupi G; Del Bufalo D
Eur J Cancer; 2009 Sep; 45(14):2618-27. PubMed ID: 19683430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
